Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy - A Monocentric, Low Interventional Phase IV Pilot Study

NCT07528586 is registered in ClinicalTrials.gov with Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) as lead sponsor.

NCT NCT07528586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07528586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy - A Monocentric, Low Interventional Phase IV Pilot Study
Lead sponsor
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Phase
Not applicable
Overall status
Recruiting
Start date
March 4, 2026
Completion date
March 31, 2030
Enrollment
93 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anthracycline-induced cardiotoxicity, cardiotoxicity